Menu
Search
Saturday, January 17, 2026

Creating liberating content

Email us
Subscribe
Menu
Search

AstraZeneca to Acquire EsoBiotec...

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

Signal12 gears up for...

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the...

The page does not exist.

Back to Homepage ⟶

― Or explore...

News

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.
Joseph George -
Press Releases

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with...
Joseph George -

Enjoy exclusive access to our content

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

Subscribe today ⟶

Amsonia Menu

Categories to explore

BahrainBiopharmaBiotechCorporateEventsFeaturesGlobal

Contribute as an author

Who we are